Brokerages Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Target Price at $8.25

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have been assigned an average recommendation of “Moderate Buy” from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $7.60.

ESPR has been the subject of a number of recent analyst reports. Needham & Company LLC raised their price objective on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Tuesday, March 3rd. HC Wainwright reiterated a “buy” rating on shares of Esperion Therapeutics in a research report on Tuesday, March 10th. Piper Sandler initiated coverage on Esperion Therapeutics in a report on Tuesday, November 25th. They issued an “overweight” rating and a $9.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Esperion Therapeutics in a research note on Thursday, January 22nd. Finally, Wall Street Zen raised Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday.

Insider Activity at Esperion Therapeutics

In other Esperion Therapeutics news, CFO Benjamin Halladay sold 7,337 shares of the business’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $3.67, for a total transaction of $26,926.79. Following the sale, the chief financial officer directly owned 467,525 shares in the company, valued at approximately $1,715,816.75. The trade was a 1.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders have sold 15,543 shares of company stock worth $55,709. 1.70% of the stock is currently owned by insiders.

Institutional Trading of Esperion Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd grew its position in Esperion Therapeutics by 17.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 36,744 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 5,492 shares during the period. Invesco Ltd. lifted its position in shares of Esperion Therapeutics by 23.5% during the 4th quarter. Invesco Ltd. now owns 765,118 shares of the biopharmaceutical company’s stock valued at $2,831,000 after acquiring an additional 145,351 shares during the period. Mackenzie Financial Corp boosted its stake in shares of Esperion Therapeutics by 23.5% during the 4th quarter. Mackenzie Financial Corp now owns 336,992 shares of the biopharmaceutical company’s stock worth $1,241,000 after acquiring an additional 64,034 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Esperion Therapeutics during the 4th quarter worth approximately $599,000. Finally, nVerses Capital LLC acquired a new stake in shares of Esperion Therapeutics in the 4th quarter worth approximately $250,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Stock Performance

Shares of ESPR opened at $2.44 on Friday. The stock has a market capitalization of $626.62 million, a P/E ratio of -14.35, a P/E/G ratio of 1.75 and a beta of 1.11. Esperion Therapeutics has a 1 year low of $0.69 and a 1 year high of $4.18. The company’s fifty day moving average is $3.28 and its two-hundred day moving average is $3.15.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.01). The firm had revenue of $168.45 million for the quarter, compared to the consensus estimate of $165.12 million. Sell-side analysts predict that Esperion Therapeutics will post -0.29 EPS for the current year.

More Esperion Therapeutics News

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Citizens Jmp raised its price target on ESPR to $5.00 (from $4.00) and assigned a “market outperform” rating — implying roughly 105% upside vs. the reference $2.44 level, which could attract buyers and trigger short‑covering. Article Title Article Title
• Neutral Sentiment: Street analysts published Q4 forecasts for ESPR; these refreshes create short‑term volatility but are routine ahead of reporting periods — watch actual Q4 results vs. the new consensus for a catalyst. Article Title
• Negative Sentiment: HC Wainwright lowered multi‑year EPS targets materially while maintaining a “Buy” rating: FY2026 cut to $0.00 (from $0.58), FY2027 to $0.25 (from $0.81) and FY2028 to $0.45 (from $1.07). The firm also models small quarterly losses (Q1 -$0.08, Q2 -$0.05, Q3 -$0.04) before the projected recovery — the revisions reduce future earnings power embedded in current valuations and likely weigh on the stock. Article Title

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.